Fig. 7

nTreg treatment prevents ileal and colonic inflammation and 3A9⁺iTreg treatment slows disease. a Prevalence of a wasting phenotype among nTreg-treated Bigenic (n = 18), nTreg-treated Ifng^–/–Bigenic (n = 12), Ifng^–/–Bigenic (n = 47) and Bigenic (n = 167) mice during the juvenile period. b Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for nTreg-treated Ifng^–/–Bigenic (n = 5), Ifng^–/–Bigenic (n = 46) and Bigenic (n = 41) mice. c, d¹ Ileal crypt depths (c) and colitis scores (d) for juvenile nTreg-treated Bigenic (n = 19), nTreg-treated Ifng^–/–Bigenic (n = 12), Ifng^–/–Bigenic (n = 17) and Bigenic (n = 19) cohorts. e, f¹ Numbers of T_H17 (e) and 3A9⁺Treg (f) cells from mLN. Juvenile nTreg-treated Ifng^–/–Bigenic (n = 12), nTreg-treated Bigenic (n = 16), Ifng^–/–Bigenic (n = 21) and Bigenic (n = 21) mice shown. g Prevalence of a wasting phenotype among 3A9⁺iTreg-treated Ifng^–/–Bigenic (n = 12), Ifng^–/–Bigenic (n = 47) and Bigenic (n = 167) mice during the juvenile period. h Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for 3A9⁺iTreg-treated Ifng^–/–Bigenic (n = 9), Ifng^–/–Bigenic (n = 46) and Bigenic (n = 41) mice. i Foxp3 expression among transferred 3A9⁺iTreg cells at endpoint for treated Ifng^–/–Bigenic^NS (n = 3) and Ifng^–/–Bigenic^S (n = 9) mice (left). Expression from Ifng^–/–Bigenic^S mice correlated to age of onset (right). ¹In 7c-7f, all Ifng^–/–Bigenic mice were symptomatic and ~90% required euthanasia before the juvenile age